BLRX BioLineRx Ltd.
Price Chart
Executive Summary
BioLineRx and partner Hemispherian AS announced that two preclinical abstracts on GLIX1, a first-in-class oral TET2 activator for glioblastoma and other solid tumors, will be presented at the ASCO 2026 Annual Meeting (May 29-June 2). The data highlight GLIX1's novel mechanism of action, strong preclinical antitumor activity in GBM xenograft models, brain penetration (68-85% of plasma levels in mice), and synergistic potential with PARP inhibitors. A Phase 1/2a clinical trial in recurrent GBM is currently enrolling, with updates expected in H2 2026 and full dose-escalation results in 2027.
Actionable Insight
ASCO abstract acceptance provides near-term catalyst visibility (May 29-June 2). However, data are preclinical and the Phase 1/2a trial is early-stage. Monitor for any additional data releases or enrollment updates during the conference. Given the $12M market cap, positive sentiment could drive outsized moves, but clinical risk remains high.
Key Facts
- Two GLIX1 abstracts accepted at ASCO 2026 (May 29-June 2, Chicago).
- GLIX1 is a first-in-class oral small molecule that reactivates TET2, inducing tumor-selective DNA strand breaks.
- Preclinical data show strong antitumor activity in multiple GBM xenograft models (U87-MG, SNB-19).
- Brain exposure after oral dosing was 68-85% of plasma levels in mice.
- GLIX1 was well-tolerated at highest doses tested: 2000 mg/kg in rats, 1000 mg/kg in dogs.
- Synergistic cytotoxic effects observed with PARP inhibitors across multiple cancer cell lines in vitro.
- Phase 1/2a trial (NCT07464925) in recurrent GBM is enrolling; dose-escalation results expected in 2027.
- BioLineRx has a $12M market cap and is a clinical-stage biopharma with no approved revenue from GLIX1.
Financial Impact
No financial figures disclosed. The filing is a preclinical data announcement with no revenue, guidance, or deal terms.
Risk Factors
- GLIX1 is in early clinical development (Phase 1/2a); no efficacy data in humans yet.
- Preclinical results may not translate to clinical benefit.
- BioLineRx has limited cash runway and may need to raise capital to fund the GLIX1 program.
- Competition in GBM and DNA damage response space is intense.
- Low market cap ($12M) increases volatility risk.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002876 |
| Document: zk2635386.htm | 0001178913-26-002876 |
| Document: 0001178913-26-002876-index-headers.html | 0001178913-26-002876 |
| Document: 0001178913-26-002876-index.html | 0001178913-26-002876 |
| Document: 0001178913-26-002876.txt | 0001178913-26-002876 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
17d ago
|
6-K
| $3.37 $3.28 | ▼ −2.67% | ▼ −3.14% | $3.37 (−0.00%) |
|
May 22, 2026
22d ago
|
6-K
| $3.06 $3.48 | ▲ +13.73% | ▲ +12.07% | $3.37 (+10.13%) |
|
May 19, 2026
25d ago
|
6-K
| $2.63 $3.23 | ▲ +22.92% | ▲ +20.67% | $3.37 (+28.14%) |
|
Mar 27, 2026
11w ago
|
3
| $2.25 $2.27 | ▲ +0.89% | ▼ −3.41% | $3.37 (+49.78%) |
|
Mar 26, 2026
11w ago
|
6-K
| $2.33 $2.21 | ▼ −5.15% | ▼ −6.78% | $3.37 (+44.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access